Get the Stockscreener App
3.30
3.76%
-0.11
Perspective Therapeutics Inc stock is traded at $3.30, with a volume of 318.05K.
It is down -3.76% in the last 24 hours and down -11.78% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.41
Open:
$3.39
24h Volume:
318.05K
Relative Volume:
0.20
Market Cap:
$230.47M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-19.23
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
-7.56%
1M Performance:
-11.78%
6M Performance:
-71.73%
1Y Performance:
-63.71%
1-Day Range:
$3.23
$3.54
1-Week Range:
$3.2206
$3.62
52-Week Range:
$2.70
$19.05
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.29 | 230.47M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
128.88 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.58 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
392.60 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.98 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Amicus Therapeutics Inc Inc. (FOLD) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Cantor Fitzgerald Weighs in on CATX FY2024 Earnings - MarketBeat
Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
The radiopharma landscape takes shape in neuroendocrine tumors - BioCentury
Its Stock Has Paid Off Big Time For Perspective Therapeutics Inc - SETE News
Perspective Therapeutics (NYSE:CATX) Raised to "Strong-Buy" at Cantor Fitzgerald - MarketBeat
CATX overperforms with a 1.52 increase in share price - US Post News
ForexTV | Small Business Resources - ForexTV.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - StockTitan
Analysts review Perspective Therapeutics Inc’s rating - Knox Daily
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Analyzing Endeavor Group Holdings Inc (EDR) After Recent Trading Activity - Knox Daily
JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Lucid raises Perspective Therapeutics stock target to $20 By Investing.com - Investing.com Australia
Lucid raises Perspective Therapeutics stock target to $20 - Investing.com India
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush - MarketBeat
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars - AOL
Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Perspective's Cancer Drug Shows Promising Results in Phase 1/2a Trial, Zero Toxicity Issues - StockTitan
Cantor Fitzgerald Forecasts CATX FY2025 Earnings - Defense World
Brokers Offer Predictions for CATX FY2025 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 - The Manila Times
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Financial Survey: Beyond Air (NASDAQ:XAIR) versus Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Perspective Therapeutics provides business updates, strategic priorities - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics Advances Cancer Pipeline with $227.8M Cash Runway Through 2026 - StockTitan
Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Neumora Therapeutics Inc (NMRA): A New Perspective - Stocks Register
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics CEO to Present at JP Morgan Healthcare Conference and Biotech Showcase - StockTitan
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Jane Street Group LLC - Defense World
John Finn named CSO of Basecamp - BioCentury
Perspective Therapeutics Appoints New Chief Financial Officer - TipRanks
Perspective Therapeutics Announces Chief Financial Officer Changes - Marketscreener.com
Perspective Therapeutics Names Juan Graham as Finance Chief - MarketWatch
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer - The Manila Times
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Geode Capital Management LLC Has $15.55 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Barclays PLC Grows Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.29%
0.14%
Cap:
|
Volume (24h):